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ABSTRACT
Background: Human papillomavirus (HPV) infection is common among men who have sex with men
(MSM), especially among Human Immunodeficiency Virus (HIV)-infected MSM. The prevalence of HPV
among MSM, accounts for the higher incidence of HPV-related cancer observed in this population. It is
well known that targeted HPV vaccination is an effective way to prevent HPV infection; an intervention
which could be beneficial for a high-risk group such as MSM. The current study aimed to assess the
attitudes towards and acceptability of the HPV vaccine among MSM in in Urumqi, China.
Methods: A total of 253 HIV-uninfected and 205 HIV-infected MSM (in Urumqi, China participated in the
current cross-sectional study. Information on HPV-related knowledge, willingness to be vaccinated as
well as demographic data were collected through a self-administered survey. A logistic regression model
was applied to determine the predictors of HPV vaccine acceptability among the population.
Results: The survey results indicated that only 218 (47.6%) of MSM questioned were aware of the term
HPV, nevertheless, once awareness was established the prevalence of acceptability of free HPV vaccine
was recorded at 96.7% of the total MSM sample. However, HIV-uninfected and HIV-infected MSM
demonstrated significantly different attitudes in regard to their acceptability of free HPV vaccination
(94.9% vs. 99.0%, p < 0.001) as well as their willingness to pay for the HPV vaccination (64.8% vs. 80.5%,
p < 0.001), with the HIV-infected group being significantly more receptive towards HPV immunization. A
multivariate logistic regression analysis indicated that local residency, employment status, hepatitis B
vaccination status, previous awareness of HPV and HIV status were independent predictors of the
participants’ willingness to pay for HPV vaccination.
Conclusions: Participants in the current study demonstrated poor knowledge of HPV but the majority of
MSM were willing to accept HPV vaccine after consultation; with HIV-infected MSM displaying higher
acceptability towards a potential HPV vaccination than HIV-uninfected MSM. MSM who were previously
aware of HPV were more likely to be willing to pay for HPV vaccine.
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Background
The human papillomavirus (HPV) is the most common sexually
transmitted infectious agent worldwide, withmore than 200 types
of HPV currently identified and around 40 of these types infect-
ing the squamous epithelium of the genital tract including the
anus, cervix, vulva and vagina.1 Previous studies showed that
HPV infections are common among men who have sex with
men (MSM), especially among HIV-infected MSM.2,3
Moreover, MSM show a particularly high prevalence of HPV in
the anal canal and with many developing lesions in the area more
frequently than any other population.4 Research suggests that the
higher prevalence of HPV among MSM compared to men who
do not have sex with men accounts for the 20 times higher
incidence of HPV-related anal cancer in the MSM population.5
More particularly previous studies amongst sexually active MSM
in China found that 33.8–62.8% had anal HPV.6-9 In addition, the
greater prevalence of HPV-related condyloma or as more com-
monly known genital warts, in MSM than for men who do not
have sex with men often results to a greater physical and mental
burden.10 It has been identified that the high-risk HPV types 16
and 18 cause the majority of HPV-associated cancers whereas the
low-risk HPV types 6 and 11 causes 90% of anogenital warts and
the most cases of recurrent respiratory papillomatosis.6,11,12
The 2017 World Health Organization position paper on
HPV vaccines recommended three HPV vaccines: 2v-HPV
vaccine (Cervarix® prevents infection with HPV types 16
and 18), 4v-HPV vaccine (Gardasil® prevents infection
with HPV types 6, 11, 16 and 18), 9v-HPV vaccine
(Gardasil® 9 prevents infection with HPV types 6, 11, 16,
18, 31, 33, 45, 52, and 58).13 The efficacy of all three HPV
vaccines has been verified by several clinical trials.14-16 By
31st March 2017, 71 countries (37%) globally (including
China) had introduced HPV vaccination in their national
immunization programs for girls whereas only 11 countries
(6%) included boys in their HPV immunization schemes.13
It is believed that China is likely to introduce existing HPV
vaccines for men in the near future.17 Surveillance data
from the Australian national 4v-HPV vaccination program
indicated that the significant decline (82%) in diagnoses of
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genital warts in young unvaccinated men who do not have
sex with men could be attributed to herd immunity con-
ferred by the high vaccination rate of females of the same
age groups, nevertheless, the authors discuss that such an
indirect protection is unlikely to benefit MSM.18
Furthermore, cost-effectiveness modelling analysis has
affirmed that HPV vaccination of MSM as a beneficial
program in preventing genital wards and anal cancer in
this high-risk population,19 with the advantage of vaccina-
tion being particularly evident in HIV-infected MSM.
In spite of efforts in recent years to raise HPV awareness,
those groups most at risk appear to remain unaware of HPV
and uncertain of the associated risks of a HPV infection,
with the phenomenon appearing more severe in HIV-
infected MSM.20 The benefits of HPV vaccination in
MSM, especially those who are HIV-infected, have been
extensively validated and reported, however, studies on
HPV knowledge and the willingness to accept HPV vacci-
nation among this high-risk population have produced
inconsistent results.21-23 Most studies concluded that MSM
have poor knowledge of HPV infection and vaccination
whilst on the other hand enhanced HPV awareness and
one’s higher education level are factors positively influen-
cing HPV vaccination acceptability. Studies on HPV knowl-
edge and vaccination willingness for HIV-infected MSM are
rare. Some studies investigated the participants’ willingness
to receive HPV vaccination mentioned the hypothesis of a
certain vaccine effectiveness and/or vaccine costs the market
price,24 however, others did not involve the price of HPV
vaccine.25,26 To develop a practical vaccination program for
MSM, it is crucial to understand the extent of awareness of
and acceptability towards HPV vaccine at a localised level.
This study aimed to investigate the differences in aware-
ness/knowledge of and acceptability towards HPV vaccina-
tion among HIV-uninfected and HIV-infected MSM in
Urumqi, China. Moreover, taking into account that it is
not currently possible to provide HPV vaccination in
China free of charge, it is particularly important to investi-
gate the willingness of MSM to pay for HPV vaccine.
Results
Characteristics of study participants
The demographic characteristics and sexual behaviors of the
study participants are summarized in Tables 1 and 2 respec-
tively. Of the total 458 MSM recruited, 218 (47.6%) were aged
30–39 years, 347 (75.8%) were local residents, 355 (77.5%)
were of Han ethnicity and 372 (81.2%) received education at
University and higher. Regarding sexual behaviors, a subset of
participants (29 participants, 6.3%) reported engaging in high-
risk behaviors such as never using condom during sex with
other men and experiencing commercial sex in the past six
months (18 participants, 3.9%). Furthermore, 65 individuals
(14.2%) reported having sex with women in the past year, 42
(9.2%) reported never having voluntary HIV counseling and
testing before, 256 (55.9%) were not circumcised and 45
(9.8%) reported having had a STDs in the past year.
Knowledge of HPV infection
The extend of overall awareness and good knowledge of HPV
and HPV infection among the recruited MSM population is
summarized in Table 3. Almost half of the participating MSM
(218, 47.6%) reported having heard of HPV before and among
those, of the participants who demonstrated awareness of
HPV, the majority (213, 97.7%) recognized that males could
be affected by HPV. Whilst the majority (214, 98.2%) of MSM
who showed awareness of HPV knew that HPV is sexually
transmitted, fewer (148, 67.9%) recognized that HPV is trans-
mitted through skin-to-skin contact. More tellingly, although
awareness that HPV infection can cause cancer was high (179,
82.1%) a smaller subset of participants (88, 40.4%) were aware
that HPV is a virus which can cause genital warts.
HPV vaccination acceptability
Results of the population’s intention to receive HPV vaccina-
tion and at what cost if they had to pay for it are displayed in
Table 4. The prevalence of acceptability of free HPV vaccina-
tion was high (443 out of 458, 96.7%), whereas, only 329
(71.8%) reported willingness to pay for HPV vaccine. It is
important to note that there were significant differences
between HIV-uninfected and HIV-infected MSM in regard
to the acceptability of a free HPV vaccine (94.9% vs. 99.0%,
p < 0.001) and the willingness to pay for HPV vaccine (64.8%
vs. 80.5%, p < 0.001). Although HIV-infect MSM were more
likely to pay for a HV vaccine, there was no difference in the
amount that the two groups (i.e. HIV-uninfected and HIV-
infected MSM) were willing to pay for the HPV vaccine.
Table 1. Demographic characteristics among 458 MSM in Urumqi, China.
Demographic Characteristics
HIV(-) HIV(+)
P value
ALL
n (%) n (%) n (%)
Age group (years) 0.002
≤ 29 103(40.7) 51(24.9) 154(33.6)
30–39 108(42.7) 110(53.7) 218(47.6)
≥ 40 42(16.6) 44(21.4) 86(18.8)
Local residency* 0.143
Yes 185(73.1) 162(79.0) 347(75.8)
No 68(26.9) 43(21.0) 111(24.2)
Ethnic group 0.636
Han 194(76.7) 161(78.5) 355(77.5)
Others 59(23.3) 44(21.5) 103(22.5)
Level of education 0.011
High school and lower 37(14.6) 49(23.9) 86(18.8)
University and higher 216(85.4) 156(76.1) 372(81.2)
Employment status 0.985
Employed 222(87.7) 180(87.8) 402(87.8)
Not employed 31(12.3) 25(12.2) 56(12.2)
Current marital status 0.001
Single 161(63.6) 157(76.6) 318(69.4)
Married 63(24.9) 22(10.7) 85(18.6)
Divorced/widowed 29(11.5) 26(12.7) 55(12)
Income (RMB) 0.130
≤ 1000 17(6.7) 16(7.8) 33(7.2)
1001–5000 171(67.6) 130(63.4) 301(65.7)
5001–10,000 60(23.7) 59(28.8) 119(26.0)
≥ 10,001 5(2.0) 0(0.0) 5(1.1)
Smoking status 0.213
Non-smokers 36(14.2) 38(18.5) 74(16.2)
Previous and current smokers 217(85.8) 167(81.5) 384(83.8)
Alcohol consumption 0.000
No 5(2.0) 32(15.6) 37(8.1)
Yes 248(98.0) 173(84.4) 421(91.9)
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Predictors of willingness to pay for HPV vaccine
The results of the univariate and multivariate logistic regres-
sion analyses deployed to evaluate the associations between
other survey variables and the willingness to pay for HPV
vaccination, are shown in Table 5. Multivariate logistic regres-
sion analysis indicated that among the studied MSM popula-
tion their local residency (OR: 2.45, 95%CI: 1.47–4.07),
employment status (OR: 1.95, 95%CI: 1.02–3.73), hepatitis B
vaccination status (OR: 0.33, 95%CI: 0.12–0.84), HPV aware-
ness (OR: 2.61, 95%CI: 1.60–4.28) and HIV status (OR: 0.54,
95%CI: 0.32–0.90) were independent predictors of the will-
ingness to pay for HPV vaccination.
Discussion
The current data showed that a large proportion of the MSM
who took part in the current survey (57.2% of total, Table 2),
commonly engage to high-risk sexual behaviors such as recep-
tive intercourse, which is a well-documented risk factor for
HPV infection.27 Interestingly, this study revealed that around
a fifth (18.6%) of the MSM population investigated was mar-
ried (i.e. to women since in China only heterosexual marriage
is currently legally allowed); a proportion that is considerably
higher than in previous research.28 This finding further
demonstrates that enhancing HPV knowledge and prevention
of HPV infection in this high-risk group in Urumqi and more
generally in China is of paramount importance in order to
prevent HPV transmission to the female partners of the sig-
nificant portion of MSM who are married. As such it is of
critical importance to recommend HPV vaccination of high-
risk MSM in order to decrease the prevalence of HPV among
this population. In-depth understanding of HPV knowledge
and HPV vaccination acceptability among local MSM will
form the basis on which a local government can formulate
informed and effective vaccination promotion strategies in the
near future. In the current study, HPV knowledge among 458
MSM was investigated, in participants who did not receive
information or explanations regarding HPV prior to complet-
ing the survey. The current results suggest that the MSM
population in Urumqi, China has poor knowledge of HPV,
at levels relatively lower than expected compared to global
data previously reported in a 2014 systematic review and
Table 2. Sexual behaviors among 458 MSM in Urumqi, China.
Sexual behaviors
HIV (-) HIV(+)
P
value
ALL
n
(%)/median
(IQR)
n
(%)/median
(IQR)
n
(%)/median
(IQR)
Age at first anal intercourse
(year)
20(18–21) 19(17–21) 0.030 19(17–21)
Self-reported sexual orientation 0.002
Gay 233(92.1) 202(98.5) 435(95.0)
Bisexual/heterosexual* 20(7.9) 3(1.5) 23(5.0)
Gender of sex partner 0.002
With men only 140(55.3) 143(69.8) 283(61.8)
Both men and women 113(44.7) 62(30.2) 175(38.2)
Pattern of anal intercourse in
the past year
0.051
Mainly receptive 155(61.3) 107(52.2) 262(57.2)
Mainly insertive 98(38.7) 98(47.8) 196(42.8)
Number of male sexual
partners in the past six
months
3(2–4) 3(2–5) 0.830 3(2–5)
Frequency of condom use during sex with other men in
the past six months
0.072
Never 12(4.7) 17(8.3) 29(6.3)
Sometimes 96(38.0) 60(29.3) 156(34.1)
Always 145(57.3) 128(62.4) 273(59.6)
Experience of commercial sex in the past six
months
0.014
Yes 15 (5.9) 3(1.5) 18(3.9)
No 238(94.1) 202(98.5) 440(96.1)
Experience of sex with women
in the past six months
0.000
Yes 55 (21.7) 10 (4.9) 65(14.2)
No 198(78.3) 195(95.1) 393(85.8)
Voluntary HIV counseling and testing 0.000
Yes 213(84.2) 203(99.0) 416(90.8)
No 40(15.8) 2(1.0) 42(9.2)
Circumcision 0.151
Yes 104(41.1) 98(47.8) 202(47.8)
No 149(58.9) 107(52.2) 256(55.9)
Hepatitis B vaccination 0.001
Yes 105(41.5) 84(41.0) 189(41.3)
No 124(49.0) 118(57.6) 242(52.8)
Unclear 24(9.5) 3(1.5) 27(5.9)
Ever had STDs in the past year 0.125
Yes 20(7.9) 25(12.2) 45(9.8)
No 233(92.1) 180(87.8) 413(90.2)
Table 3. Awareness and knowledge of HPV among 458 MSM in Urumqi, China.
ALL HIV(-) HIV(+)
Knowledge on HPV n (%) n (%) n (%) P value
Ever heard of HPV 0.227
Yes 218(47.6) 114(45.1) 104(50.7)
No 240(52.4) 139(54.9) 101(49.3)
Of those who responded Yes above
Males could be affected by HPV 0.144
Yes# 213(97.7) 113(99.1) 100(96.2)
No/Uncertain 5(2.3) 1(0.9) 4(3.8)
HPV is transmitted through skin to skin contact 0.860
Yes# 148(67.9) 78(68.4) 70(67.3)
No/Uncertain 70(32.1) 36(31.6) 34(32.7)
HPV is sexually transmitted 0.359
Yes# 214(98.2) 111(97.4) 103(99.0)
No/Uncertain 4(1.8) 3(2.6) 1 (1.0)
HPV is a virus that can cause genital warts 0.000
Yes# 88(40.4) 68(59.6) 20(19.2)
No/Uncertain 130(59.6) 46(40.4) 84(80.8)
HPV is a virus that can cause cancer 0.009
Yes# 179(82.1) 101(88.6) 78(75.0)
No/Uncertain 39(17.9) 13 (11.4) 26(25.0)
Notes: HIV (-) denotes HIV-uninfected MSM whereas HIV (+) denotes HIV-infected
MSM.
The option with the # symbol is the correct response.
Table 4. Intention to receive HPV vaccination among 458 MSM in Urumqi, China.
Intention to
receive HPV
vaccination
HIV(-) HIV(+)
P value
ALL
n(%)/median
(IQR)
n(%)/median
(IQR)
n(%)/median
(IQR)
Willing to receive HPV vaccination for free < 0.001
Yes 240(94.9) 203(99.0) 443(96.7)
No 13(5.1) 2(1.0) 15(3.3)
Willing to pay to receive vaccination < 0.001
Yes 164(64.8) 165(80.5) 329(71.8)
No 89(35.2) 40(19.5) 129(28.2)
How much would
you pay for the
HPV vaccination
(RMB)?
200(100–300) 200(100–425) 0.335 200(100–350)
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other studies conducted out of China.22,29 Although the pro-
portion of individuals who were aware of HPV is higher
among HIV-infected MSM than that of HIV-uninfected,
among those who knew about HPV, HIV-uninfected had a
greater correct responses rate to further survey items than
HIV-infected individuals. More generally the findings of
these study clearly indicate that improvement of HPV knowl-
edge of transmission, risk factors and prevention among MSM
especially high-risk MSM in Urumqi.
Furthermore, most participants in the current study were
highly educated and as such it is presumed that their HPV
awareness could potentially be significantly higher than that
of a less educated MSM cohort, which in turn suggests that
the real-life HPV awareness in Urumqi MSM may be lower
than that observed in the current study population. In China,
there is a significant correlation between local residency and
social status,30 with an individual being considered of a higher
social status if they are a local resident. Local residents refer to
those born in Urumqi, and registered in the Urumqi (who
have registry status with the local “hukou”), nonlocal residents
refer to those born in other cities. Most non-local residents
were come from small city or rural areas where are less
developed, they came to Urumqi for making money, or
attending college. The majority of MSM in the current survey
were local residents and their willingness to pay for HPV
vaccine, could be attributed to the relatively higher social
status that compared to non-local residents. Along with the
higher social status these individuals are more likely to have
more access to social resources, HPV related information and
are more conscious about their health; this is supported by
evidence indicating that migrants have a higher risk of STIs
and hepatitis than the general Chinese population.31
Therefore, when promoting HPV vaccination programs, it
would be easier to begin with local residents who are already
more receptive to the idea of receiving HPV vaccine and then
gradually engage with non-local residents who will require
more education and longer time to engage with the programs.
At the same time, in order to ensure a higher coverage rate of
vaccines, for non-local residents, it is appropriate to imple-
ment HPV knowledge promotion strategies firstly to enhance
Table 5. Univariate and multivariate logistic regression analysis of risk factors for intention to receive HPV vaccination in 458 MSM in Urumqi,
China.
Characteristics N COR (95%CI) P value AOR (95%CI) P value
Local residency
Yes 347 Ref. Ref.
No 111 2.50 (1.59–3.92) < 0.001 2.45 (1.47–4.07) 0.001
Ethnic group
Han 355 Ref.
Others 103 1.60 (1.00–2.56) 0.048
Employment status
Employed 402 Ref. Ref.
Not employed 56 2.12 (1.19–3.76) 0.010 1.95 (1.02–3.73) 0.043
Self-reported sexual orientation
Gay 435 Ref.
Bisexual/
heterosexual*
23 4.23 (1.82–10.27) 0.001
Gender of sex partner
With men only 283 Ref.
Both men and
women
175 1.84 (1.22–2.79) 0.004
Frequency of condom use during sex with other men in the past six months
Never 29 Ref. 0.045
Sometimes 156 1.29 (0.53–3.15) 0.571
Always 273 0.75 (0.31–1.79) 0.517
Experience of commercial sex in the past six months
Yes 18 Ref.
No 440 0.47 (0.18–1.23) 0.125
Experience of sex with women in the past six months
Yes 65 Ref.
No 393 0.39 (0.23–0.70) 0.001
Engaging in voluntary HIV counseling and testing
Yes 416 Ref.
No 42 2.85 (1.49–5.42) 0.001
Hepatitis B
vaccination
Yes 189 Ref. < 0.001 Ref. < 0.001
No 242 0.33 (0.21–0.52) < 0.001 0.90 (0.36–2.28) 0.837
Unclear 27 1.71 (0.76–3.84) 0.193 0.33 (0.12–0.84) 0.020
Ever heard of HPV
Yes 218 Ref. Ref.
No 240 3.19 (2.05–4.97) < 0.001 2.61(1.60–4.28) < 0.001
HIV diagnosis
Uninfected 253 Ref. Ref.
Infected 205 0.44 (0.29–0.68) 0.000 0.54 (0.32–0.90) 0.019
Notes: Univariately non-significant variables were not listed in this table; COR: crude odds ratio; AOR: adjusted OR, 95% CI: 95% confidence
interval. * Men who identify themselves as heterosexual but defined as MSM due to reporting having anal and/or oral sex with other men
in the last 12 months prior to participation in the study. Ethnic group, Self-reported sexual orientation, Gender of sex partner, Experience
of sex with women in the past six months, Engaging in voluntary HIV counseling and testing were adjusted for calculated AOR.
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their HPV knowledge. As shown in the current study employ-
ment status is also significantly associated with acceptability
of HPV vaccination. In China unemployed people receive
relatively little assistance form the state which might explain
the lack of willingness to accept HPV vaccination either
because healthcare is sidetracked by other everyday needs or
because of the perceive costs of HPV vaccination and their
inability to personally cover the cost.
The demonstrated lack of appropriate knowledge of HPV
infection may potentially influence the population’s percep-
tion of the need to adopt preventive behaviors which are
often influenced by the perceived susceptibility and severity
of a condition. The findings and exposed weaknesses indi-
cated by the current research could provide the focus points
for targeted future improvements in HPV awareness. To
promote the newly available HPV vaccines among MSM, it
is essential to increase the populations awareness and under-
standing of HPV; this could be done through a variety or
combination of means such as Internet, social media, multi-
media and NGO promotions as well as in school health
education workshops targeted to both students and school
staff and face-to-face HPV education intervention sessions
both for healthcare staff and patents. This will make it easier
for MSM to obtain the correct knowledge of HPV and
improve vaccine acceptability, whilst promoting the issue
to the general public. Despite limited knowledge of HPV
among the total MSM cohort, the majority of MSM were
willing to accept HPV vaccination when assumed this would
be provided free of charge by a healthcare provider. The
current data show that the percentage of the MSM popula-
tion willing to pay to receive HPV vaccination (proposed
cost not disclosed to participants) was higher than previous
studies where the cost of HPV vaccination was disclosed to
participants.21,32–34 This indicates that the cost of the HPV
vaccination could be a potentially great impediment to the
MSM population’s willingness to be vaccinated for HPV. All
HPV vaccines are currently charged in China, therefore, the
willingness of the interviewed MSM population to pay for
the vaccine is a meaningful reflection of the applicability of
the data in real life.35 The observed significantly increased
willingness to pay for HPV vaccination in the HIV-infected
MSM compared to HIV-uninfected MSM population in the
current study might be due to differences in risk conscious-
ness; HIV-infected MSM may pay more attention to their
health conditions and may think they have higher risk of
HPV infection and as such are willing to pay to receive HPV
vaccination. Previous findings have shown that individuals
who are more aware of potential risks to their health are
more likely to engage in self-protective behaviors.36 More
tellingly, other studies have shown that assessments of HPV
infection risk and awareness of HPV were contributing fac-
tors to the acceptability of HPV vaccination.36,37 The cur-
rently licensed HPV vaccines are likely to be effective in
HIV-infected individuals38 thus there utilization in the
HIV-infected MSM population demonstrating higher will-
ingness to receive HPV vaccination could be imminent once
government approval has been granted. Collectively the evi-
dence suggests that the local government should carefully
consider recommending HPV vaccination for all MSM, but
especially for HIV-infected MSM. HIV clinics are concen-
trated large number of HIV-infected MSM could be targeted
would be a good starting point for promoting HPV knowl-
edge and HPV immunization programs.
To promote HPV vaccination among MSM effectively, it is
critical to understand the factors that influence the willingness
to pay for HPV vaccine. In the current study it was concluded
that at least five variables investigated (local residency,
employment status, hepatitis B vaccination, awareness of
HPV and HIV status) were all significantly associated with
acceptability of HPV vaccination. The current findings indi-
cating that MSM who were aware of HPV were more likely to
pay for HPV vaccination than these who had never heard of
HPV, are in agreement with previous results from a study
conducted in Canada,39 this study included 1169 MSM,
among them, 67.0% were willing to receive HPV vaccine
and 71.3% had heard of HPV, and indicated that HPV vac-
cines acceptability varied by demographics, risk, and HPV
awareness.
Besides, in addition to improving MSM’s HPV related
knowledge, reducing risky sexual behavior is also an impor-
tant aspect of reducing HPV transmission and infection. A
large proportion of MSM in the current study was married to
women, signaling the importance of taking action to reduce
HPV transmission between MSM and also women. Examples
of how this can be done include further education MSM
regarding the use of condoms when engaging in sex with
both sexes and by engaging eligible female partners in receiv-
ing HPV vaccine. At present, China’s HPV immunizations on
offer are still relatively expensive (about 5800RMB) and
starkly different to the average cost of 200RMB for the HPV
vaccine the study participants were willing to pay. It can be
suggested that reducing the cost of HPV vaccination substan-
tially would play a critical role in increasing HPV immuniza-
tion coverage for both MSM and females. At present, experts
in China have been conducting Randomized clinical trials
(RCTs) for domestic HPV vaccines; If the results are favorable
and the after the domestic vaccines successfully marketed in
China, the price of HPV vaccines could be greatly reduced,
thus the government could promote a policy that government
will pay for HPV vaccines, as the authority already covered
HIV treatment for all clinics. All these would significantly
enhancing HPV immunization coverage.
It is acknowledged that some limitations in the study
design may have affected the observed outcomes. Firstly,
participant selection bias cannot be excluded since we used
non-probability convenience sample in the current study and
MSM were only recruited from two sites where a large pro-
portion of the participants (81%) had reported having a uni-
versity degree.; As such the study population would only
represent views of a highly educated sub-group of MSM. In
fact, at the sites involved in the participant recruitment in the
current study, it has been observed that less-educated MSM
generally do not routinely engage in HIV counseling and
testing, and thus the results of the current study cannot be
generalized to the wider MSM population. Secondly, there is a
chance of self-reported bias; For instance, since the survey
administered questions on potentially sensitive sexual beha-
viors, it is possible that some perceived positive behaviors (e.g.
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frequency of condom use) were exaggerated whilst some
perceived negative behaviors (e.g. number of sexual partners)
were underestimated by participants in an attempt to be
viewed more favorably by the assessors. Thirdly, no informa-
tion was collected from HIV-infected MSM in regard to
receiving antiretroviral therapy (ART), adherence and virolo-
gical suppression, therefore, any bias these parameters may
confer on the study results cannot be excluded. However,
since the HIV-infected MSM we recruited from a single
HIV clinic, where ART is routinely provided, it could be
suggested that HIV-infected MSM in the current study were
probably on ART but still adherence and viral load suppres-
sion remain unknown. Lastly, as specified earlier refusal to
participate was not monitored, as such the population
recruited in the study could have had a increased interest in
HPV and extent resulting to an overestimation of HPV accep-
tance among the general population.
Conclusions
In summary, the participants in the current study had overall
poor knowledge of HPV nonetheless after a consultation the
majority of MSM surveyed were willing to accept HPV vacci-
nation, with HIV-infected individual having a dramatically
higher acceptability rate of HPV vaccination than HIV-unin-
fected MSM. Furthermore, participating MSM who had some
previous awareness of HPV were more likely to pay for HPV
vaccination. Collectively these results illustrate that future
promotion of HPV vaccination should also focus on the
promotion of HPV-related knowledge, while paying close
attention to HIV-infected MSM.
Materials and methods
Study population
A cross-sectional survey was performed between January 1st
and April 30th 2017, to investigate HPV vaccination accept-
ability among HIV-uninfected and HIV-infected MSM in
Urumqi, China. Participants were recruited through conve-
nience sampling from two sites: HIV-uninfected MSM
(n = 253) through a local NGO (Tian’Shan Volunteers
Workstation) and HIV-infected MSM (n = 205) through a
HIV outpatient clinic (Infectious Diseases Hospital of
Xinjiang). For the purposes of the current research, MSM
was defined as men who had anal and/or oral sex with other
men in the last 12 months prior to participation in the study,
including men who identified themselves as heterosexual.
Potential MSM participants were eligible if they were
18 years or older and willing to consent to taking part in
the current study. Refusal to participate in the study was not
recorded. In order to confirm the HIV status of participants
recruited through the NGO site, 8 ml venous blood was
collected and their HIV infection status was initially deter-
mined by an enzyme immunoassay (4 ml venous blood,
Wantai Biological Pharmacy, Beijing, China) and subse-
quently confirmed by HIV-1/2 Western blot assay (4 ml
venous blood, HIV Blot 2.2 WB; Genelabs Diagnostics,
Singapore). The results confirmed that all of the participants
recruited through the NGO site were HIV-uninfected. All
recruited MSM completed a study survey (the average com-
pletion time was 10 min) in a private consultation room. All
participants were compensated with 30 RMB (approximately
four and half US dollars) for their time.
Data collection
The self-administered survey including a series of single item
questions was designed by the research team and was based
on previously published studies examining HPV vaccine
acceptability in MSM.21, 32, 33, 40 The experts selected items
that they thought could reflect HPV knowledge and vaccina-
tion intentions based on literature and experience. The survey
was piloted among 25 participants prior to implementation.
Information on socio-demographic characteristics such as age,
marital status, residency location, income and education were
collected. Firstly, HPV awareness was assessed (i.e. survey
question item “Ever heard of HPV”). Once awareness was
established further survey questions were asked (see Table 3)
to decipher the extend of the participants’ HPV relevant
knowledge Only the ones who said they were aware of HPV
were included in the later survey questions that asked about
HPV knowledge. Secondly, the acceptability of HPV vaccina-
tion among MSM was assessed by the following survey ques-
tion items (see Table 4): 1) Willing to receive HPV
vaccination for free; 2) Willing to pay for receiving vaccina-
tion; and 3) How much would you pay for the HPV vaccina-
tion (RMB) (a continuous variable and participants could
write in any amount).
Statistical analysis
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was utilized for
the statistical analysis. Basic demographics were reported as
totals and percentages. Comparisons between the two groups
were performed through chi-squared tests. A univariate logistic
regression model was developed to evaluate associations
between each variable under investigation and their willingness
to pay for HPV vaccination. All variables in the univariate
analysis which yielded p-values < 0.05 were entered into a
multivariate logistic regression model to determine any inde-
pendent predictors of the willingness to pay for HPV vaccina-
tion. Crude odds ratios (COR) and adjusted odds ratios (AOR)
were calculated along with 95% confidence intervals (CIs).
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